4Lilleby K. A prospective, randomized study of cryotherapy during administration of high- dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation[J]. Bone marrow tramsplant, 2006, 37 ( 11 ) : 1 031-1 035.
5[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
6[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
7[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
8[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
9[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
10[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144
